Inactive Instrument

Aytu Bioscience Inc Stock price Nasdaq

Equities

US0547544033

Pharmaceuticals

Sales 2024 * 83.55M Sales 2025 * 77.08M Capitalization 16.93M
Net income 2024 * -12M Net income 2025 * 2M EV / Sales 2024 * 0.2 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 0.22 x
P/E ratio 2024 *
-1.36 x
P/E ratio 2025 *
6.08 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.52%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Aytu BioPharma, Inc., Q2 2024 Earnings Call, Feb 14, 2024
Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q2 Revenue $22.9M, vs. Street Est of $21.75M MT
Aytu BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
Transcript : Aytu BioPharma, Inc., Q1 2024 Earnings Call, Nov 14, 2023
Earnings Flash (AYTU) AYTU BIOPHARMA Posts Q1 Revenue $22.1M, vs. Street Est of $27.7M MT
Aytu BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023 CI
Aytu BioPharma Gets FDA Approval to Transfer Production of Cotempla to Third Party MT
Aytu BioPharma, Inc. Announces Approval of the Cotempla XR-ODT Manufacturing Site Transfer Prior Approval Supplement CI
Aytu BioPharma, Inc. Announces Resignation of Christopher Brooke as Chief Operating Officer CI
Earnings Flash (AYTU) AYTU BIOPHARMA Posts Q4 Revenue $30.7M, vs. Street Est of $27.7M MT
Aytu BioPharma, Inc. Reports Earnings Results for the Fourth Quarter Ended June 30, 2023 CI
Aytu BioPharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023 CI
North American Morning Briefing : Stock Futures Helped by Retreating Bond Yields DJ
Maxim Starts Aytu BioPharma at Buy With $5 Price Target MT
Aytu BioPharma, Inc. Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-OT(R) in Israel and the Arab Authority CI
More news
Managers TitleAgeSince
Chief Executive Officer 49 15-04-15
Founder 49 15-04-15
Director of Finance/CFO 55 22-01-16
Members of the board TitleAgeSince
Director/Board Member 62 22-06-30
Founder 49 15-04-15
Chief Executive Officer 49 15-04-15
More insiders
Aytu BioPharma, Inc. is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics and consumer health products. The Company’s Rx segment consists of prescription pharmaceutical products and the Consumer Health segment consists of various consumer healthcare products (the Consumer Health Portfolio). The Company’s prescription products include Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (ADHD); Karbinal ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions; and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Its Consumer Health Segment addresses a range of common conditions.
More about the company
  1. Stock
  2. Equities
  3. Stock Aytu BioPharma, Inc.
  4. Stock Aytu Bioscience Inc - Nasdaq